Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Fusion Pharmaceuticals (FUSN) News Today

Fusion Pharmaceuticals logo
Fusion Finance Ltd (FUSN)
Fusion Pharma (FUSN) Earnings Dates & Reports
Fusion Pharmaceuticals Inc. stock logo
Avidity Partners Management LP Increases Holdings in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Avidity Partners Management LP raised its holdings in shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) by 12.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,500,328 shar
Fusion Pharmaceuticals Inc. stock logo
Superstring Capital Management LP Takes $440,000 Position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Superstring Capital Management LP bought a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 45,801 shares of the company's stock, valued a
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Average Recommendation of "Hold" by Analysts
Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) have been assigned a consensus recommendation of "Hold" from the fourteen ratings firms that are presently covering the company, MarketBeat reports. Thirteen investment analysts have rated the stock with a hold rating and one ha
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals (NASDAQ:FUSN) Sets New 12-Month High at $21.60
Fusion Pharmaceuticals (NASDAQ:FUSN) Sets New 52-Week High at $21.60
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals (NASDAQ:FUSN) Sees Large Volume Increase
Fusion Pharmaceuticals (NASDAQ:FUSN) Sees Large Volume Increase
Fusion Pharmaceuticals Inc. stock logo
Jump Financial LLC Invests $828,000 in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Jump Financial LLC acquired a new stake in shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 86,199 shares of the company's stock, valued at approximately $828,000. Jump Financial LLC owne
Fusion Pharmaceuticals Inc. stock logo
Q2 2024 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Boosted by William Blair
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Investment analysts at William Blair lifted their Q2 2024 earnings per share (EPS) estimates for Fusion Pharmaceuticals in a research note issued on Tuesday, May 7th. William Blair analyst A. Hsieh now forecasts that the company will post
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Sees Significant Drop in Short Interest
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 4,860,000 shares, a decline of 6.5% from the March 31st total of 5,200,000 shares. Based on an average daily trading volume, of 2,140,000 shares, the days-to-cover ratio is currently 2.3 days.
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals (NASDAQ:FUSN) Hits New 12-Month High at $21.56
Fusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 52-Week High at $21.56
Fusion Pharmaceuticals Inc. stock logo
Jennison Associates LLC Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Jennison Associates LLC purchased a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 301,020 shares of the company's stock, valued at approximat
Fusion Pharmaceuticals Inc Ordinary Shares
Fusion Pharmaceuticals Inc. stock logo
Federated Hermes Inc. Acquires 202,364 Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Federated Hermes Inc. lifted its holdings in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,886,153 shares of the company's stock
Fusion Pharmaceuticals Inc. stock logo
HealthInvest Partners AB Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
HealthInvest Partners AB acquired a new position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 125,000 shares of the company's stock, valued at approximately $1,
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals (NASDAQ:FUSN) Earns "Hold" Rating from TD Cowen
TD Cowen restated a "hold" rating on shares of Fusion Pharmaceuticals in a research report on Tuesday.
Fusion Pharmaceuticals Inc. stock logo
Leerink Partnrs Analysts Cut Earnings Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Analysts at Leerink Partnrs cut their Q1 2024 earnings estimates for Fusion Pharmaceuticals in a note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.37)
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 12-Month High at $21.55
Fusion Pharmaceuticals (NASDAQ:FUSN) Hits New 1-Year High at $21.55
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Short Interest Down 8.3% in March
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 7,920,000 shares, a decrease of 8.3% from the February 29th total of 8,640,000 shares. Based on an average daily volume of 2,210,000 shares, the short-interest ratio is presently 3.6 days.
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 1-Year High at $21.32
Fusion Pharmaceuticals (NASDAQ:FUSN) Sets New 52-Week High at $21.32
Fusion Pharmaceuticals Inc. stock logo
Yarbrough Capital LLC Acquires Shares of 76,872 Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Yarbrough Capital LLC acquired a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 76,872 shares of the company's stock, valued at approximately $739,0
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Expected to Earn FY2023 Earnings of ($1.36) Per Share
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Equities researchers at Bloom Burton lifted their FY2023 earnings per share (EPS) estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 20th. Bloom Burton analyst D. Martin
Fusion Pharmaceuticals Inc. stock logo
FY2026 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Raised by Analyst
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Investment analysts at Wedbush increased their FY2026 earnings estimates for shares of Fusion Pharmaceuticals in a note issued to investors on Tuesday, March 19th. Wedbush analyst D. Nierengarten now expects that the company will post earn
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals (NASDAQ:FUSN) Downgraded by Bloom Burton
Bloom Burton downgraded Fusion Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday.
Unveiling 11 Analyst Insights On Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc. stock logo
B. Riley Reiterates "Neutral" Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)
B. Riley reissued a "neutral" rating and issued a $23.00 price objective (up previously from $13.00) on shares of Fusion Pharmaceuticals in a research report on Wednesday.
Fusion Pharmaceuticals Inc. stock logo
Fusion Pharmaceuticals (NASDAQ:FUSN) Downgraded to "Market Perform" at Leerink Partnrs
Leerink Partnrs cut Fusion Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Tuesday.
Get Fusion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

FUSN Media Mentions By Week

FUSN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FUSN
News Sentiment

0.00

0.59

Average
Medical
News Sentiment

FUSN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FUSN Articles
This Week

0

2

FUSN Articles
Average Week

Get Fusion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:FUSN) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners